Cold Sore Treatment Guidelines

Oral Antiviral Medications

The American Academy of Dermatology recommends valacyclovir (2g twice daily for 1 day) as a first-line treatment for cold sores, which reduces median duration of episodes by 1.0 day compared to placebo (p=0.001) 1, 2
Famciclovir (1500mg single dose) is also effective, significantly reducing time to healing of primary lesions compared to placebo, with a strength of evidence rated as high 1, 3
Both valacyclovir and famciclovir offer more convenient dosing schedules than acyclovir for herpes labialis, with a moderate strength of evidence 1, 4
Early initiation of therapy is critical, with treatment starting during the prodromal phase or within 24 hours of symptom onset for best results, based on strong evidence 2

Topical antivirals provide modest clinical benefit but are less effective than oral therapy, with a low strength of evidence 3, 4
Topical antivirals are not effective for prophylaxis as they cannot reach the site of viral reactivation, based on moderate evidence 3, 4

First-line therapy is oral valacyclovir 2g twice daily for 1 day, initiated at earliest symptoms, with a high strength of evidence 2
Alternative oral therapy is famciclovir 1500mg as a single dose, with a moderate strength of evidence 1, 3

Dose adjustment may be required in patients with significant renal impairment, based on low evidence 2
For immunocompromised patients, higher doses or longer treatment durations may be required, with a moderate strength of evidence 2
Resistance to antiviral medications remains low (<0.5%) in immunocompetent hosts but may be higher in immunocompromised patients, based on strong evidence 2, 5

Relying solely on topical treatments when oral therapy is more effective, with a high strength of evidence 3, 4
Inadequate dosing, such as not using short-course, high-dose therapy, which is more effective than traditional longer courses, based on moderate evidence 4

Short-course, high-dose antiviral therapy offers greater convenience, cost benefits, and may improve patient adherence, with a moderate strength of evidence 3, 4